These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 26917816)

  • 1. Ranolazine and Its Effects on Hemoglobin A1C.
    Greiner L; Hurren K; Brenner M
    Ann Pharmacother; 2016 May; 50(5):410-5. PubMed ID: 26917816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihyperglycemic and Metabolic Effects of Ranolazine in Patients With Diabetes Mellitus.
    Gilbert BW; Sherard M; Little L; Branstetter J; Meister A; Huffman J
    Am J Cardiol; 2018 Feb; 121(4):509-512. PubMed ID: 29274809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ranolazine on glycaemic control in patients with type 2 diabetes treated with either glimepiride or metformin.
    Pettus J; McNabb B; Eckel RH; Skyler JS; Dhalla A; Guan S; Jochelson P; Belardinelli L; Henry RH
    Diabetes Obes Metab; 2016 May; 18(5):463-74. PubMed ID: 26749407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c.
    Arnold SV; McGuire DK; Spertus JA; Li Y; Yue P; Ben-Yehuda O; Belardinelli L; Jones PG; Olmsted A; Chaitman BR; Kosiborod M
    Am Heart J; 2014 Oct; 168(4):457-465.e2. PubMed ID: 25262254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome.
    Chisholm JW; Goldfine AB; Dhalla AK; Braunwald E; Morrow DA; Karwatowska-Prokopczuk E; Belardinelli L
    Diabetes Care; 2010 Jun; 33(6):1163-8. PubMed ID: 20357382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ranolazine for stable angina pectoris.
    Salazar CA; Basilio Flores JE; Veramendi Espinoza LE; Mejia Dolores JW; Rey Rodriguez DE; Loza Munárriz C
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD011747. PubMed ID: 28178363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.
    Goldstein BJ; Feinglos MN; Lunceford JK; Johnson J; Williams-Herman DE;
    Diabetes Care; 2007 Aug; 30(8):1979-87. PubMed ID: 17485570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R; Aguilar R; Hehnke U; Woerle HJ; von Eynatten M
    Clin Ther; 2014 Nov; 36(11):1595-605. PubMed ID: 25236917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.
    Jarvis CI; Cabrera A; Charron D
    Ann Pharmacother; 2013 Nov; 47(11):1532-9. PubMed ID: 24285765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Pediatric Type 2 Diabetes.
    Smith JD; Mills E; Carlisle SE
    Ann Pharmacother; 2016 Sep; 50(9):768-77. PubMed ID: 27307414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
    Goldman J; White JR
    Ann Pharmacother; 2015 Oct; 49(10):1153-61. PubMed ID: 26238470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
    Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Katz A; Jones PG; Olmsted A; Belardinelli L; Chaitman BR
    J Am Coll Cardiol; 2013 May; 61(20):2038-45. PubMed ID: 23500237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Canagliflozin treatment of Hispanic and non-Hispanic patients with type 2 diabetes in a US managed care setting.
    Chow W; Buysman E; Rupnow MF; Aguilar R; Henk HJ
    Curr Med Res Opin; 2016; 32(1):13-22. PubMed ID: 26414434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes: A Meta-analysis.
    Palmer SC; Mavridis D; Nicolucci A; Johnson DW; Tonelli M; Craig JC; Maggo J; Gray V; De Berardis G; Ruospo M; Natale P; Saglimbene V; Badve SV; Cho Y; Nadeau-Fredette AC; Burke M; Faruque L; Lloyd A; Ahmad N; Liu Y; Tiv S; Wiebe N; Strippoli GF
    JAMA; 2016 Jul; 316(3):313-24. PubMed ID: 27434443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis.
    Park H; Park C; Kim Y; Rascati KL
    Ann Pharmacother; 2012 Nov; 46(11):1453-69. PubMed ID: 23136353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis.
    McIntosh B; Cameron C; Singh SR; Yu C; Ahuja T; Welton NJ; Dahl M
    Open Med; 2011; 5(1):e35-48. PubMed ID: 22046219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.
    Liu SC; Tu YK; Chien MN; Chien KL
    Diabetes Obes Metab; 2012 Sep; 14(9):810-20. PubMed ID: 22486990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control and weight gain in type 2 diabetes: a network meta-analysis.
    Gross JL; Kramer CK; Leitão CB; Hawkins N; Viana LV; Schaan BD; Pinto LC; Rodrigues TC; Azevedo MJ;
    Ann Intern Med; 2011 May; 154(10):672-9. PubMed ID: 21576535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.